company background image
CPRX

Catalyst Pharmaceuticals NasdaqCM:CPRX Stock Report

Last Price

US$12.41

Market Cap

US$1.3b

7D

-3.0%

1Y

145.7%

Updated

27 Sep, 2022

Data

Company Financials +
CPRX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance3/6
Financial Health6/6
Dividends0/6

CPRX Stock Overview

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.

Catalyst Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Catalyst Pharmaceuticals
Historical stock prices
Current Share PriceUS$12.41
52 Week HighUS$17.22
52 Week LowUS$5.00
Beta1.31
1 Month Change-11.48%
3 Month Change78.56%
1 Year Change145.74%
3 Year Change148.20%
5 Year Change368.30%
Change since IPO103.44%

Recent News & Updates

Sep 12

Catalyst Pharmaceuticals gains 9% on SmallCap 600 addition

Catalyst Pharmaceuticals (NASDAQ:CPRX) has jumped 8.6% after hours following word that the stock will join the S&P SmallCap 600 index. Catalyst is set to replace ManTech International (MANT) in the list. The Carlyle Group is nearing the close of its acquisition of ManTech. The change is effective prior to the open of trading on Thursday, Sept. 15.

Shareholder Returns

CPRXUS BiotechsUS Market
7D-3.0%-3.3%-5.8%
1Y145.7%-27.4%-22.1%

Return vs Industry: CPRX exceeded the US Biotechs industry which returned -30.6% over the past year.

Return vs Market: CPRX exceeded the US Market which returned -23.7% over the past year.

Price Volatility

Is CPRX's price volatile compared to industry and market?
CPRX volatility
CPRX Average Weekly Movement10.1%
Biotechs Industry Average Movement11.0%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: CPRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: CPRX's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200276Pat McEnanyhttps://www.catalystpharma.com

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies.

Catalyst Pharmaceuticals Fundamentals Summary

How do Catalyst Pharmaceuticals's earnings and revenue compare to its market cap?
CPRX fundamental statistics
Market CapUS$1.28b
Earnings (TTM)US$54.50m
Revenue (TTM)US$170.47m

23.4x

P/E Ratio

7.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CPRX income statement (TTM)
RevenueUS$170.47m
Cost of RevenueUS$43.13m
Gross ProfitUS$127.34m
Other ExpensesUS$72.84m
EarningsUS$54.50m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.53
Gross Margin74.70%
Net Profit Margin31.97%
Debt/Equity Ratio0%

How did CPRX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is CPRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CPRX?

Other financial metrics that can be useful for relative valuation.

CPRX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.2x
Enterprise Value/EBITDA14.5x
PEG Ratio1.6x

Price to Earnings Ratio vs Peers

How does CPRX's PE Ratio compare to its peers?

CPRX PE Ratio vs Peers
The above table shows the PE ratio for CPRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average23.8x
CDMO Avid Bioservices
9.2x-21.9%US$1.1b
EBS Emergent BioSolutions
10.6x38.7%US$1.0b
XNCR Xencor
66.4x18.8%US$1.5b
IRWD Ironwood Pharmaceuticals
9.1x12.8%US$1.6b
CPRX Catalyst Pharmaceuticals
23.4x14.8%US$1.3b

Price-To-Earnings vs Peers: CPRX is good value based on its Price-To-Earnings Ratio (23.4x) compared to the peer average (23.8x).


Price to Earnings Ratio vs Industry

How does CPRX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Earnings vs Industry: CPRX is expensive based on its Price-To-Earnings Ratio (23.4x) compared to the US Biotechs industry average (13.8x)


Price to Earnings Ratio vs Fair Ratio

What is CPRX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CPRX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio23.4x
Fair PE Ratio23.4x

Price-To-Earnings vs Fair Ratio: CPRX is expensive based on its Price-To-Earnings Ratio (23.4x) compared to the estimated Fair Price-To-Earnings Ratio (23.4x).


Share Price vs Fair Value

What is the Fair Price of CPRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CPRX ($12.41) is trading below our estimate of fair value ($45.97)

Significantly Below Fair Value: CPRX is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Catalyst Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


14.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CPRX's forecast earnings growth (14.8% per year) is above the savings rate (1.9%).

Earnings vs Market: CPRX's earnings (14.8% per year) are forecast to grow faster than the US market (14.7% per year).

High Growth Earnings: CPRX's earnings are forecast to grow, but not significantly.

Revenue vs Market: CPRX's revenue (12.2% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: CPRX's revenue (12.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CPRX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Catalyst Pharmaceuticals performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


56.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CPRX has high quality earnings.

Growing Profit Margin: CPRX's current net profit margins (32%) are lower than last year (58.8%).


Past Earnings Growth Analysis

Earnings Trend: CPRX has become profitable over the past 5 years, growing earnings by 56.5% per year.

Accelerating Growth: CPRX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: CPRX had negative earnings growth (-27%) over the past year, making it difficult to compare to the Biotechs industry average (29.2%).


Return on Equity

High ROE: CPRX's Return on Equity (22.6%) is considered high.


Discover strong past performing companies

Financial Health

How is Catalyst Pharmaceuticals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: CPRX's short term assets ($242.6M) exceed its short term liabilities ($22.5M).

Long Term Liabilities: CPRX's short term assets ($242.6M) exceed its long term liabilities ($3.7M).


Debt to Equity History and Analysis

Debt Level: CPRX is debt free.

Reducing Debt: CPRX has not had any debt for past 5 years.

Debt Coverage: CPRX has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CPRX has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Catalyst Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Catalyst Pharmaceuticals Dividend Yield vs Market
How does Catalyst Pharmaceuticals dividend yield compare to the market?
SegmentDividend Yield
Company (Catalyst Pharmaceuticals)n/a
Market Bottom 25% (US)1.7%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (Catalyst Pharmaceuticals)n/a

Notable Dividend: Unable to evaluate CPRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CPRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CPRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CPRX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CPRX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

6.6yrs

Average management tenure


CEO

Pat McEnany (75 yo)

20.67yrs

Tenure

US$2,089,432

Compensation

Mr. Patrick J. McEnany, also known as Pat, co-founded Catalyst Pharmaceuticals, Inc. (formerly known as Catalyst Pharmaceutical Partners Inc.) in January 2002 and has been its Chairman and President since...


CEO Compensation Analysis

Pat McEnany's Compensation vs Catalyst Pharmaceuticals Earnings
How has Pat McEnany's remuneration changed compared to Catalyst Pharmaceuticals's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

US$54m

Mar 31 2022n/an/a

US$45m

Dec 31 2021US$2mUS$632k

US$39m

Sep 30 2021n/an/a

US$42m

Jun 30 2021n/an/a

US$75m

Mar 31 2021n/an/a

US$72m

Dec 31 2020US$2mUS$604k

US$75m

Sep 30 2020n/an/a

US$71m

Jun 30 2020n/an/a

US$42m

Mar 31 2020n/an/a

US$43m

Dec 31 2019US$3mUS$548k

US$32m

Sep 30 2019n/an/a

US$9m

Jun 30 2019n/an/a

-US$12m

Mar 31 2019n/an/a

-US$29m

Dec 31 2018US$3mUS$524k

-US$34m

Sep 30 2018n/an/a

-US$25m

Jun 30 2018n/an/a

-US$21m

Mar 31 2018n/an/a

-US$19m

Dec 31 2017US$901kUS$485k

-US$18m

Sep 30 2017n/an/a

-US$17m

Jun 30 2017n/an/a

-US$17m

Mar 31 2017n/an/a

-US$18m

Dec 31 2016US$608kUS$473k

-US$18m

Sep 30 2016n/an/a

-US$20m

Jun 30 2016n/an/a

-US$20m

Mar 31 2016n/an/a

-US$20m

Dec 31 2015US$1mUS$453k

-US$20m

Compensation vs Market: Pat's total compensation ($USD2.09M) is below average for companies of similar size in the US market ($USD5.63M).

Compensation vs Earnings: Pat's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CPRX's management team is seasoned and experienced (6.6 years average tenure).


Board Members

Experienced Board: CPRX's board of directors are seasoned and experienced ( 14.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CPRX insiders have only sold shares in the past 3 months.


Recent Insider Transactions

NasdaqCM:CPRX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
23 Sep 22SellUS$713,940Alicia GrandeIndividual60,000US$11.90
16 Sep 22SellUS$1,214,640Alicia GrandeIndividual90,000US$13.50
14 Sep 22SellUS$472,000Philip CoelhoIndividual30,000US$15.75
14 Sep 22SellUS$15,832,731Patrick McEnanyIndividual1,027,611US$15.41
14 Sep 22SellUS$306,800Donald DenkhausIndividual20,000US$15.34
14 Sep 22SellUS$778,650Alicia GrandeIndividual50,000US$15.57
13 Sep 22SellUS$1,824,367Steven MillerIndividual107,933US$17.11
29 Aug 22SellUS$969,328Alicia GrandeIndividual68,095US$14.40
19 Aug 22SellUS$198,667Jeffrey Del CarmenIndividual14,140US$14.05

Ownership Breakdown

What is the ownership structure of CPRX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders6,472,7886.3%
Hedge Funds10,200,0009.9%
General Public19,631,68519.1%
Institutions66,515,03164.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 59.37% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.92%
Armistice Capital LLC
10,200,000$126.6m21.83%2.93%
6.76%
BlackRock, Inc.
6,951,816$86.3m-6.59%no data
5.29%
State Street Global Advisors, Inc.
5,437,479$67.5m17.75%no data
4.73%
The Vanguard Group, Inc.
4,861,988$60.3m2.71%no data
3.92%
LSV Asset Management
4,029,677$50.0m8.81%0.1%
3.8%
Patrick McEnany
3,902,606$48.4m-20.84%no data
2.65%
Millennium Management LLC
2,723,895$33.8m134.05%0.04%
2.18%
Dimensional Fund Advisors LP
2,242,648$27.8m4.54%0.01%
2.04%
Royce & Associates, LP
2,100,225$26.1m-7.15%0.24%
1.65%
Geode Capital Management, LLC
1,691,792$21.0m-3.54%no data
1.41%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
1,449,757$18.0m107.65%0.01%
1.39%
D. E. Shaw & Co., L.P.
1,427,050$17.7m36.96%0.03%
1.35%
Acadian Asset Management LLC
1,391,566$17.3m-8.55%0.06%
1.28%
Northern Trust Global Investments
1,316,132$16.3m-0.28%no data
1.26%
Goldman Sachs Asset Management, L.P.
1,293,275$16.0m42.91%0.01%
1.15%
Charles Schwab Investment Management, Inc.
1,181,407$14.7m42.1%no data
1.05%
Two Sigma Advisers, LP
1,077,292$13.4m-12.7%0.04%
1.01%
Allianz Asset Management AG
1,039,545$12.9m13.55%0.01%
1%
J.P. Morgan Asset Management, Inc.
1,032,865$12.8m-0.5%no data
1%
Renaissance Technologies LLC
1,031,612$12.8m192.15%0.02%
0.97%
PGIM, Inc.
996,995$12.4m-12.09%0.02%
0.97%
Morgan Stanley, Investment Banking and Brokerage Investments
994,361$12.3m19.31%no data
0.94%
Jacobs Levy Equity Management Inc
967,060$12.0m-22.33%0.09%
0.89%
Invesco Capital Management LLC
913,999$11.3m108.2%0.01%
0.76%
Allspring Global Investments, LLC
785,564$9.7m-27.14%0.01%

Company Information

Catalyst Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Catalyst Pharmaceuticals, Inc.
  • Ticker: CPRX
  • Exchange: NasdaqCM
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$1.276b
  • Shares outstanding: 102.82m
  • Website: https://www.catalystpharma.com

Number of Employees


Location

  • Catalyst Pharmaceuticals, Inc.
  • 355 Alhambra Circle
  • Suite 801
  • Coral Gables
  • Florida
  • 33134
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CPRXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2006
CN2DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2006

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/27 00:00
End of Day Share Price2022/09/27 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.